Biocon Biologics announces positive results from Phase 3 Study of Yesintek biosimilar to Ustekinumab… EP News Bureau Mar 8, 2025 The safety profile of YESINTEK was similar to the reference product Stelara (Ustekinumab) throughout the duration of the study
Biocon Biologics launches YESINTEK, a Stelara biosimilar, in the United States EP News Bureau Feb 25, 2025 Biocon Biologics enters US market with YESINTEK, offering treatment options for Crohn’s disease, ulcerative colitis, plaque…
Biocon Biologics’ Ustekinumab Biosimilar receives positive CHMP opinion EP News Bureau Dec 16, 2024 YESINTEK recommended for approval to treat psoriasis, psoriatic arthritis, and Crohn’s disease in adults and children
